English
Back
Open Account
富途资讯
wrote a column · Jun 5 07:37

New IPO Pricing | Tianchen Bio-B debuts today, receiving over 4,700 times subscription, priced at HK$96.06 per share, with an off-market gain of HK$2,742 per lot

Futu News, June 5: $LONGBIO-B (01779.HK)$ announced its allotment results, pricing shares at HK$96.06 each, issuing a total of 14.1932 million shares, with a board lot size of 50 shares, officially listing today.
On the previous trading day, Techent Bio-B's grey market closed up 57.09% at HK$150.90. With a board lot of 50 shares, each lot generated a profit of HK$2,742, excluding fees.
During the public offering phase, Techent Bio-B received 4,762.58 times subscription demand. The final number of shares allocated to the public offering was 1.4194 million shares, representing approximately 10% of the total offering. A total of approximately 266,400 valid applications were received, with about 28,057 applications processed. The approximate percentage of applicants who received one lot out of all applications was 2%.
Additionally, during the international placement phase, Techent Bio-B received 10.94 times subscription demand. The final number of shares allocated to the international offering was 12.7738 million shares, equivalent to 90% of the total offering. Futu compiled the relevant data in the table below:
Futu News, June 5: $LONGBIO-B (01779.HK)$ announced its allotment results, pricing shares at HK$96.06 each, issuing a total of 14.1932 million shares, with a board lot size of 50 shares, officially listing today. On the previous trading day, Tianchen Bio-B’s off-market price closed up 57.09% at HK$150.90, with a board lot of 50 shares, yielding a pre-fee profit of HK$2,742 per lot. During the public offering stage, Tianchen Bio-B received 4,762.58 times subscription. The final number of shares allocated to the public offering was 1.4194 million shares, representing approximately 10% of the total offering. A total of approximately 266,400 valid applications were received, with about 28,057 applications processed, and the percentage of applicants who applied for one lot and received an allotment relative to total applied shares was approximately 2%. Additionally, during the international placing stage, Tianchen Bio-B received 10.94 times subscription. The final number of shares allocated to the international offering was 12.7738 million shares, accounting for 90% of the total offering. Futu News has compiled the relevant data in the table below: Company Overview The company is a clinical-stage biopharmaceutical company founded in 2020, headquartered in Shanghai and Changshu, Suzhou, China. It primarily focuses on the independent discovery and development of biologics targeting allergic and autoimmune diseases. The company has built a comprehensive pipeline of biologics targeting conditions in rhinology, dermatology, respiratory medicine, hematology, nephrology, and other autoimmune disorders...
Futu News, June 5: $LONGBIO-B (01779.HK)$ announced its allotment results, pricing shares at HK$96.06 each, issuing a total of 14.1932 million shares, with a board lot size of 50 shares, officially listing today. On the previous trading day, Tianchen Bio-B’s off-market price closed up 57.09% at HK$150.90, with a board lot of 50 shares, yielding a pre-fee profit of HK$2,742 per lot. During the public offering stage, Tianchen Bio-B received 4,762.58 times subscription. The final number of shares allocated to the public offering was 1.4194 million shares, representing approximately 10% of the total offering. A total of approximately 266,400 valid applications were received, with about 28,057 applications processed, and the percentage of applicants who applied for one lot and received an allotment relative to total applied shares was approximately 2%. Additionally, during the international placing stage, Tianchen Bio-B received 10.94 times subscription. The final number of shares allocated to the international offering was 12.7738 million shares, accounting for 90% of the total offering. Futu News has compiled the relevant data in the table below: Company Overview The company is a clinical-stage biopharmaceutical company founded in 2020, headquartered in Shanghai and Changshu, Suzhou, China. It primarily focuses on the independent discovery and development of biologics targeting allergic and autoimmune diseases. The company has built a comprehensive pipeline of biologics targeting conditions in rhinology, dermatology, respiratory medicine, hematology, nephrology, and other autoimmune disorders...
Company Overview
The company is a clinical-stage biopharmaceutical company founded in 2020, headquartered in Shanghai and Changshu, Suzhou, China. It primarily focuses on the independent discovery and development of biologics targeting allergic and autoimmune diseases. The company has built a comprehensive pipeline of biologic drug candidates covering rhinology, dermatology, respiratory, hematology, nephrology, and other autoimmune disease areas.
The company's lead product, LP-003, is an anti-IgE antibody featuring a novel sequence design. LP-003 primarily functions by blocking free IgE in blood and tissues, thereby inhibiting IgE-mediated allergic reactions. IgE is central to the mechanism of Type I hypersensitivity. Type I hypersensitivity, triggered by allergens in various organs, causes seasonal allergic rhinitis (AR), allergic asthma, chronic spontaneous urticaria (CSU), food allergies, and other allergic conditions.
Financial Summary
For the years 2024 and 2025, Techent Bio-B reported total comprehensive losses of RMB 137.3 million and RMB 175.6 million, respectively.
Futu News, June 5: $LONGBIO-B (01779.HK)$ announced its allotment results, pricing shares at HK$96.06 each, issuing a total of 14.1932 million shares, with a board lot size of 50 shares, officially listing today. On the previous trading day, Tianchen Bio-B’s off-market price closed up 57.09% at HK$150.90, with a board lot of 50 shares, yielding a pre-fee profit of HK$2,742 per lot. During the public offering stage, Tianchen Bio-B received 4,762.58 times subscription. The final number of shares allocated to the public offering was 1.4194 million shares, representing approximately 10% of the total offering. A total of approximately 266,400 valid applications were received, with about 28,057 applications processed, and the percentage of applicants who applied for one lot and received an allotment relative to total applied shares was approximately 2%. Additionally, during the international placing stage, Tianchen Bio-B received 10.94 times subscription. The final number of shares allocated to the international offering was 12.7738 million shares, accounting for 90% of the total offering. Futu News has compiled the relevant data in the table below: Company Overview The company is a clinical-stage biopharmaceutical company founded in 2020, headquartered in Shanghai and Changshu, Suzhou, China. It primarily focuses on the independent discovery and development of biologics targeting allergic and autoimmune diseases. The company has built a comprehensive pipeline of biologics targeting conditions in rhinology, dermatology, respiratory medicine, hematology, nephrology, and other autoimmune disorders...
Use of Proceeds
Regarding the use of proceeds, Techent Bio-B expects net proceeds from the global offering to amount to approximately HK$1.255 billion (based on an issue price of HK$96.06). According to the prospectus, Techent Bio-B intends to allocate the funds raised from the global offering for the following purposes:
Approximately 75.0% will be primarily used for the research and development and commercialization of core and key products, approximately 15.0% will be allocated to further develop other preclinical pipeline products and R&D platforms, and approximately 10.0% will be used for working capital and other general corporate purposes.
The golden season for new stock subscriptions has arrived! Use Futu for new stock subscriptions—zero interest, zero handling fees, and zero cash subscription. Participants now have the chance to have their new stock subscription fees waived for a year.Come and experience it now >>
Futu News, June 5: $LONGBIO-B (01779.HK)$ announced its allotment results, pricing shares at HK$96.06 each, issuing a total of 14.1932 million shares, with a board lot size of 50 shares, officially listing today. On the previous trading day, Tianchen Bio-B’s off-market price closed up 57.09% at HK$150.90, with a board lot of 50 shares, yielding a pre-fee profit of HK$2,742 per lot. During the public offering stage, Tianchen Bio-B received 4,762.58 times subscription. The final number of shares allocated to the public offering was 1.4194 million shares, representing approximately 10% of the total offering. A total of approximately 266,400 valid applications were received, with about 28,057 applications processed, and the percentage of applicants who applied for one lot and received an allotment relative to total applied shares was approximately 2%. Additionally, during the international placing stage, Tianchen Bio-B received 10.94 times subscription. The final number of shares allocated to the international offering was 12.7738 million shares, accounting for 90% of the total offering. Futu News has compiled the relevant data in the table below: Company Overview The company is a clinical-stage biopharmaceutical company founded in 2020, headquartered in Shanghai and Changshu, Suzhou, China. It primarily focuses on the independent discovery and development of biologics targeting allergic and autoimmune diseases. The company has built a comprehensive pipeline of biologics targeting conditions in rhinology, dermatology, respiratory medicine, hematology, nephrology, and other autoimmune disorders...
Editor/Joe
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Thumbs Up
7
227K Views
Report
Comment (1)
Write a Comment...
1
7
12